Sentiment-Signal
11,9
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 04.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 03.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 06.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 30.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 19.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 31.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment o |
| 14.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 10.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | eive the payments and other benefits described in Item 5.02 below subject to meeting the terms thereof, but there is no |
Stammdaten
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Unternehmen & Branche
| Name | Perspective Therapeutics, Inc. |
|---|---|
| Ticker | CATX |
| CIK | 0000728387 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 288,0 Mio. USD |
| Beta | 1,87 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -103,121,000 | -1.40 | 266,972,000 | 207,031,000 | |
| 2025-09-30 | 10-Q | -25,969,000 | -0.35 | 294,825,000 | 242,216,000 | |
| 2025-06-30 | 10-Q | -21,485,000 | -0.29 | 310,725,000 | 265,692,000 | |
| 2025-03-31 | 10-Q | -18,177,000 | -0.25 | 329,349,000 | 284,645,000 | |
| 2024-12-31 | 10-K | -79,279,000 | -1.23 | 341,101,000 | 290,668,000 | |
| 2024-09-30 | 10-Q | -15,122,000 | -0.21 | 391,153,000 | 328,471,000 | |
| 2024-06-30 | 10-Q | -11,704,000 | -0.18 | 385,919,000 | 340,997,000 | |
| 2024-03-31 | 10-Q | -12,284,000 | -0.25 | 278,286,000 | 229,891,000 | |
| 2023-12-31 | 10-K | -46,508,000 | -1.74 | 97,891,000 | 75,179,000 | |
| 2023-09-30 | 10-Q | 2,185,000 | -10,356,000 | -0.37 | 110,518,000 | 98,770,000 |
| 2023-06-30 | 10-Q | 2,088,000 | -11,106,000 | -0.40 | 120,145,000 | 108,653,000 |
| 2023-03-31 | 10-Q | 2,063,000 | -371,000 | 0.00 | 127,645,000 | 118,028,000 |
| 2022-12-31 | 10-K | -7,335,000 | 58,091,000 | 54,642,000 | ||
| 2022-09-30 | 10-Q | 1,717,000 | -4,068,000 | 62,538,000 | 57,702,000 | |
| 2022-06-30 | 10-Q | 2,505,000 | -2,078,000 | 64,439,000 | 61,277,000 | |
| 2022-06-30 | 10-K | 2,505,000 | -2,078,000 | 64,439,000 | 61,277,000 | |
| 2022-03-31 | 10-Q | 2,910,000 | -1,347,000 | 66,113,000 | 63,201,000 | |
| 2022-03-31 | 10-K | 2,910,000 | -1,347,000 | |||
| 2021-12-31 | 10-K | 2,816,000 | -1,604,000 | |||
| 2021-12-31 | 10-Q | -1,604,000 | 67,252,000 | 64,391,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-13 | Hunt Jonathan Robert | Officer, Chief Accounting Officer | Open Market Purchase | 11,000 | 2.03 | 22,294.80 | +105,6% | |
| 2025-11-12 | Williamson Robert F III | Director | Open Market Purchase | 9,498 | 2.10 | 19,945.80 | +94,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.